The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease
This study has been completed.
Sponsor:
Bispebjerg Hospital
Information provided by:
Bispebjerg Hospital
ClinicalTrials.gov Identifier:
NCT00252018
First received: November 10, 2005
Last updated: May 13, 2008
Last verified: May 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to investigate whether a daily intake of dried broccoli sprouts will improve the endothelial function of the participants as measured by Flow mediated dilation (FMD)
The dried sprouts are chosen because broccoli sprouts are known as containing large amounts af the glucosinolate glucoraphanin which in vitro and in animal models has been shown to have a positive effect on the endothelium as measured by NO release.
| Condition | Intervention |
|---|---|
|
Diabetes Mellitus Hypertension Hypercholesterolemia Cardiovascular Disease |
Behavioral: Daily intake of broccoli sprouts |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention |
| Official Title: | The Effect of Broccoli Sprouts as a Nutritional Supplement in the Prevention of Cardiovascular Disease. |
Resource links provided by NLM:
Further study details as provided by Bispebjerg Hospital:
Primary Outcome Measures:
- Improvement of endothelial function as measured by FMD
| Estimated Enrollment: | 160 |
| Study Start Date: | January 2006 |
| Study Completion Date: | March 2007 |
| Primary Completion Date: | March 2007 (Final data collection date for primary outcome measure) |
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients suffering from hypertension, having a diastolic blood pressure of above 90 mm Hg or a systolic blood pressure of more than 140 mm Hg.
- Patients suffering from NIDDM, according to present criteria for diagnosis of NIDDM:
- People with dyslipidemia (combination of total cholesterol above 5, LDL cholesterol above 3 and HDL cholesterol below 1.1)
- Healthy controls suffering from none of the above conditions, but otherwise (age, sex, BMI and lifestyle) corresponding to the patient groups.
Exclusion Criteria:
- Patients under the age of 18 at inclusion in the study.
- Pregnant or breastfeeding women
- Women of childbearing age with no safe method of contraception
- Patients receiving vitamin K-antagonists (coumarine, marcoumar etc)
Contacts and Locations
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00252018 History of Changes |
| Other Study ID Numbers: | KF 01-257/04 |
| Study First Received: | November 10, 2005 |
| Last Updated: | May 13, 2008 |
| Health Authority: | Denmark: National Board of Health |
Keywords provided by Bispebjerg Hospital:
|
Nutritional supplement Prevention Endothelial function Flow mediated dilation |
Additional relevant MeSH terms:
|
Cardiovascular Diseases Diabetes Mellitus Hypercholesterolemia Hypertension Glucose Metabolism Disorders Metabolic Diseases |
Endocrine System Diseases Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Vascular Diseases |
ClinicalTrials.gov processed this record on May 23, 2013